BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:vidofludimus calcium readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of vidofludimus calcium\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05201638-9637@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05201638)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety and Tolerability of IMU-838 in Patie
 nts With Relapsing Multiple Sclerosis\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludimu
 s-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05201638
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05134441-9637@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05134441)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety\, and Tolerability of IMU-838 in Pat
 ients With Relapsing Multiple Sclerosis\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludi
 mus-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05134441
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
